NCT03834623View on ClinicalTrials.gov

Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 14, 2019

Primary Completion Date

June 29, 2021

Study Completion Date

August 4, 2021

Conditions
Melanoma
Interventions
DRUG

CC-122

Oral CC-122 at 2 mg daily, 5 days out of 7

DRUG

Nivolumab

240 mg Nivolumab intravenously days 1 and 15 in each 28 day cycle

Trial Locations (1)

33612

H Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Celgene Corporation

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER